Showing 1 - 10 of 10 results
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
AR-13503 is an active metabolite of Netarsudil
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Sotrastaurin, an orally-active, first-in-class immunomodulator, is under development by Novartis for the treatment of uveal melanoma and diffuse-large B-cell lymphoma. Sotrastaurin is a low molecular mass synthetic compound
that potently inhibits the...
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Ruboxistaurin is an orally bioavailable, selective, potent inhibitor of protein kinase C β developed for treating diabetic retinopathy. In vitro and in vivo non-clinical models have demonstrated that Ruboxistaurin decreases PKC β activity and amelio...
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
AR-13503 is an active metabolite of Netarsudil
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
AR-13503 is an active metabolite of Netarsudil
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
AR-13503 is an active metabolite of Netarsudil
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Ruboxistaurin is an orally bioavailable, selective, potent inhibitor of protein kinase C β developed for treating diabetic retinopathy. In vitro and in vivo non-clinical models have demonstrated that Ruboxistaurin decreases PKC β activity and amelio...
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Sotrastaurin, an orally-active, first-in-class immunomodulator, is under development by Novartis for the treatment of uveal melanoma and diffuse-large B-cell lymphoma. Sotrastaurin is a low molecular mass synthetic compound
that potently inhibits the...
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Ruboxistaurin is an orally bioavailable, selective, potent inhibitor of protein kinase C β developed for treating diabetic retinopathy. In vitro and in vivo non-clinical models have demonstrated that Ruboxistaurin decreases PKC β activity and amelio...
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Ruboxistaurin is an orally bioavailable, selective, potent inhibitor of protein kinase C β developed for treating diabetic retinopathy. In vitro and in vivo non-clinical models have demonstrated that Ruboxistaurin decreases PKC β activity and amelio...